USBC director granted 5.24M options; repriced 4.76M options
Rhea-AI Filing Summary
Insider option activity: A director, Linda Jenkinson, reported option repricings and new grants on 10/07/2025 for USBC, Inc. The Board approved lowering the exercise price of previously granted options from $2.45 to $1.10 for 4,760,000 shares. The reporting person also received two option grants: one repriced option covering 4,760,000 shares and a new option for 5,240,000 shares, creating total option exposure to 10,000,000 underlying shares exercisable through 2035. Each option vests 25% after one year then quarterly over three years.
Positive
- Vesting schedule aligns with service-based retention: options vest 25% after one year then quarterly over three years
- Long-term alignment: options expire in 2035, creating a multi-year incentive horizon
Negative
- Significant potential dilution: 10,000,000 underlying shares granted or repriced could be material to outstanding share count
- Repricing reduces exercise price from $2.45 to $1.10, which may concern shareholders about previous grant pricing or retention cost
Insights
Repricing and a large new grant raise dilution and retention questions.
The Board reduced the exercise price from $2.45 to $1.10 for an existing option covering 4.76M shares and granted an additional 5.24M-share option to a director, totaling 10M underlying shares with 2035 expirations. Vesting is standard: 25% after one year then quarterly over three years, aligning pay-for-service.
Key dependencies include the company’s outstanding share count and potential dilution impact to equity per-share metrics; monitor filings for total shares outstanding and any shareholder authorization for repricings within the next 12 months.
Board-approved repricing suggests retention or correction of prior strike pricing.
Repricing of options requires Board approval and often follows assessments of competitiveness or remediation of option pricing errors. The action affects senior-level incentives and could trigger shareholder scrutiny if dilution is material relative to the cap table.
Watch for disclosure of the company’s equity plan capacity, any related-party approval details, and subsequent Schedule 13D/G or proxy disclosures within the next fiscal year that quantify dilution and governance rationale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Option to Purchase Common Stock | 4,760,000 | $0.00 | -- |
| Grant/Award | Option to Purchase Common Stock | 4,760,000 | $0.00 | -- |
| Grant/Award | Option to Purchase Common Stock | 5,240,000 | $0.00 | -- |
Footnotes (1)
- The transactions reported involved the repricing of outstanding stock options to purchase 4,760,000 shares of common stock of USBC, Inc. (the "Company") pursuant to the Amended and Restated USBC, Inc. 2021 Equity Incentive Plan (the "Amended and Restated 2021 Plan"), initially granted on August 6, 2025 (the "Grant Date"). The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years. On October 7, 2025, in accordance with the terms of the Amended and Restated 2021 Plan, the Board of Directors of the Company approved a repricing of outstanding stock options granted on August 6, 2025. The exercise price of each repriced option was reduced from $2.45 to $1.10 per share. On October 7, 2025, the Reporting Person was granted an option to purchase 5,240,000 shares of the Company's common stock pursuant to the Amended and Restated 2021 Plan. The option will vest as to 25% of the shares covered by the option on the one-year anniversary of the Grant Date and in quarterly installments thereafter over the next three years.
